Joanna Zhang

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised the underwriters of Aardvark Therapeutics, a phase 3 biotech company developing novel small-molecule therapies for metabolic diseases, in connection with Aardvark’s $94.2 million initial public offering (IPO).

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.

Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.